research use only

D-Cycloserine Selection Antibiotics for Transfected Cell inhibitor

Name: D-Cycloserine
Brand: Selleck Chemicals
SKU: S1998
Rating: 5 (1 reviews)

Cat.No.S1998

D-cycloserine (RO-1-9213) is an analogue of the amino acid D-alanine, used as an antibiotic in the treatment of tuberculosis.

Chemical Structure

Molecular Weight: 102.09

Jump to

Quality Control

Batch: Purity: 99.97%

99.97

Related Targets	Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV
Other Selection Antibiotics for Transfected Cell Inhibitors	Blasticidin S Hydrochloride Ribostamycin Sulfate

Chemical Information, Storage & Stability

Molecular Weight	102.09	Formula	C₃H₆N₂O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	68-41-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	RO-1-9213			Smiles	C1C(C(=O)NO1)N

Solubility

In vitro
Batch:

Water : 20 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vivo

D-cycloserine (DCS) facilitates extinction of conditioned freezing to the light CS when no drug pre-exposure has occurred, but pre-exposure to DCS just prior to conditioning disrupted the facilitation of extinction effect in mice. D-cycloserine (DCS) which has a high affinity for the glycine modulatory site in the NMDA receptor complex modulated memory processing in a dose-dependent manner. DCS also facilitates retention in 'senescence-accelerated mice' in which impairment of learning and memory increases with age. D-cycloserine (DCS) exhibits facilitated extinction of fear but are able to reacquire fear of that conditioned stimulus (CS) in a similar manner as saline-treated control rats. DCS-treated rats exhibits generalized extinction (i.e., they are less fearful of a non-extinguished CS) in comparison to controls. D-cycloserine (DCS), an antimycobacterial agent known to cross the blood-brain barrier, binds with high affinity to this glycine modulatory site, functions as a positive modulator, and facilitates performance of learning tasks in rats. DCS appears to be a potent cognitive enhancer at doses lower than those required for antibacterial activity. D-cycloserine injections (3.25, 15, or 30 mg/kg) before 30 non-reinforced light exposures dose-dependently enhances extinction but does not influence fear-potentiated startle in rats that does not receive extinction training.

References

[1] https://pubmed.ncbi.nlm.nih.gov/15820858/
[2] https://pubmed.ncbi.nlm.nih.gov/1330624/
[3] https://pubmed.ncbi.nlm.nih.gov/15820704/

[4] https://pubmed.ncbi.nlm.nih.gov/2560209/
[5] https://pubmed.ncbi.nlm.nih.gov/11896173/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05731323	Completed	Major Depressive Disorder	University of Calgary	October 12 2022	Phase 1
NCT01399866	Completed	Smoking Cessation	Massachusetts General Hospital	May 2011	Phase 3
NCT00964041	Withdrawn	Schizophrenia	Massachusetts General Hospital\|National Institute of Mental Health (NIMH)	July 2009	Phase 4
NCT01062932	Completed	Nicotine Addiction	Baylor College of Medicine\|National Institute on Drug Abuse (NIDA)	May 2009	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):